vs
Amphastar Pharmaceuticals, Inc.（AMPH）とBLACKBAUD INC（BLKB）の財務データ比較。上の社名をクリックして会社を切り替えられます
BLACKBAUD INCの直近四半期売上が大きい（$281.1M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.5倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 11.1%、差は2.3%）。BLACKBAUD INCの前年同期比売上増加率が高い（4.2% vs -1.8%）。BLACKBAUD INCの直近四半期フリーキャッシュフローが多い（$37.0M vs $24.6M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -1.1%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Blackbaud社は非営利組織、財団、企業、教育機関、医療機関、宗教団体、社会変革を推進する個人を支援するクラウドコンピューティングプロバイダーです。製品は資金調達、ウェブサイト管理、CRM、分析、財務管理、チケット発行、教育行政などの分野に特化しています。
AMPH vs BLKB — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $281.1M |
| 純利益 | $24.4M | $31.1M |
| 粗利率 | 46.8% | 59.2% |
| 営業利益率 | 19.4% | 18.3% |
| 純利益率 | 13.3% | 11.1% |
| 売上前年比 | -1.8% | 4.2% |
| 純利益前年比 | -35.7% | 620.3% |
| EPS（希薄化後） | $0.51 | $0.67 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $281.1M | ||
| Q4 25 | $183.1M | $295.3M | ||
| Q3 25 | $191.8M | $281.1M | ||
| Q2 25 | $174.4M | $282.0M | ||
| Q1 25 | $170.5M | $269.9M | ||
| Q4 24 | $186.5M | $302.1M | ||
| Q3 24 | $191.2M | $286.6M | ||
| Q2 24 | $182.4M | $287.3M |
| Q1 26 | — | $31.1M | ||
| Q4 25 | $24.4M | $36.7M | ||
| Q3 25 | $17.4M | $47.5M | ||
| Q2 25 | $31.0M | $26.5M | ||
| Q1 25 | $25.3M | $4.3M | ||
| Q4 24 | $38.0M | $-346.4M | ||
| Q3 24 | $40.4M | $18.3M | ||
| Q2 24 | $37.9M | $21.2M |
| Q1 26 | — | 59.2% | ||
| Q4 25 | 46.8% | 58.3% | ||
| Q3 25 | 51.4% | 59.6% | ||
| Q2 25 | 49.6% | 59.7% | ||
| Q1 25 | 50.0% | 57.5% | ||
| Q4 24 | 46.5% | 53.8% | ||
| Q3 24 | 53.3% | 54.9% | ||
| Q2 24 | 52.2% | 56.0% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | 19.4% | 20.0% | ||
| Q3 25 | 13.2% | 19.4% | ||
| Q2 25 | 24.2% | 20.3% | ||
| Q1 25 | 21.9% | 7.3% | ||
| Q4 24 | 24.2% | -121.5% | ||
| Q3 24 | 29.8% | 14.4% | ||
| Q2 24 | 30.3% | 14.4% |
| Q1 26 | — | 11.1% | ||
| Q4 25 | 13.3% | 12.4% | ||
| Q3 25 | 9.0% | 16.9% | ||
| Q2 25 | 17.8% | 9.4% | ||
| Q1 25 | 14.8% | 1.6% | ||
| Q4 24 | 20.4% | -114.6% | ||
| Q3 24 | 21.1% | 6.4% | ||
| Q2 24 | 20.8% | 7.4% |
| Q1 26 | — | $0.67 | ||
| Q4 25 | $0.51 | $0.75 | ||
| Q3 25 | $0.37 | $0.98 | ||
| Q2 25 | $0.64 | $0.55 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.74 | $-6.82 | ||
| Q3 24 | $0.78 | $0.35 | ||
| Q2 24 | $0.73 | $0.41 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $34.1M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $34.6M |
| 総資産 | $1.6B | $2.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $34.1M | ||
| Q4 25 | $282.8M | $38.9M | ||
| Q3 25 | $276.2M | $38.3M | ||
| Q2 25 | $231.8M | $41.6M | ||
| Q1 25 | $236.9M | $37.2M | ||
| Q4 24 | $221.6M | $67.6M | ||
| Q3 24 | $250.5M | $34.6M | ||
| Q2 24 | $217.8M | $30.4M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $1.1B | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $1.1B | ||
| Q3 24 | $596.4M | $1.0B | ||
| Q2 24 | $586.9M | $1.0B |
| Q1 26 | — | $34.6M | ||
| Q4 25 | $788.8M | $85.1M | ||
| Q3 25 | $776.7M | $108.2M | ||
| Q2 25 | $757.5M | $72.7M | ||
| Q1 25 | $751.3M | $17.5M | ||
| Q4 24 | $732.3M | $126.8M | ||
| Q3 24 | $727.7M | $544.8M | ||
| Q2 24 | $713.3M | $577.5M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.7B | $2.1B | ||
| Q2 25 | $1.6B | $2.6B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $1.6B | $2.5B | ||
| Q3 24 | $1.5B | $2.6B | ||
| Q2 24 | $1.5B | $3.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 13.06× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 8.50× | ||
| Q3 24 | 0.82× | 1.84× | ||
| Q2 24 | 0.82× | 1.78× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $51.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $37.0M |
| FCFマージンFCF / 売上 | 13.4% | 13.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 1.65× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $294.1M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $51.5M | ||
| Q4 25 | $32.9M | $58.0M | ||
| Q3 25 | $52.6M | $139.2M | ||
| Q2 25 | $35.6M | $66.9M | ||
| Q1 25 | $35.1M | $1.4M | ||
| Q4 24 | $29.0M | $73.6M | ||
| Q3 24 | $60.0M | $104.0M | ||
| Q2 24 | $69.1M | $53.1M |
| Q1 26 | — | $37.0M | ||
| Q4 25 | $24.6M | $55.0M | ||
| Q3 25 | $47.2M | $135.7M | ||
| Q2 25 | $25.0M | $66.3M | ||
| Q1 25 | $24.4M | $712.0K | ||
| Q4 24 | $16.6M | $73.4M | ||
| Q3 24 | $46.2M | $102.9M | ||
| Q2 24 | $63.1M | $48.0M |
| Q1 26 | — | 13.2% | ||
| Q4 25 | 13.4% | 18.6% | ||
| Q3 25 | 24.6% | 48.3% | ||
| Q2 25 | 14.3% | 23.5% | ||
| Q1 25 | 14.3% | 0.3% | ||
| Q4 24 | 8.9% | 24.3% | ||
| Q3 24 | 24.1% | 35.9% | ||
| Q2 24 | 34.6% | 16.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 1.0% | ||
| Q3 25 | 2.8% | 1.2% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | 0.1% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 1.8% |
| Q1 26 | — | 1.65× | ||
| Q4 25 | 1.35× | 1.58× | ||
| Q3 25 | 3.03× | 2.93× | ||
| Q2 25 | 1.15× | 2.53× | ||
| Q1 25 | 1.39× | 0.32× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 5.69× | ||
| Q2 24 | 1.82× | 2.50× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
BLKB
セグメントデータなし
